JNJ

235.44

+0.84%↑

UNH

276.85

-1.86%↓

TMO

566.56

-0.62%↓

ABT

109.39

+0.52%↑

ISRG

476.98

-0.36%↓

JNJ

235.44

+0.84%↑

UNH

276.85

-1.86%↓

TMO

566.56

-0.62%↓

ABT

109.39

+0.52%↑

ISRG

476.98

-0.36%↓

JNJ

235.44

+0.84%↑

UNH

276.85

-1.86%↓

TMO

566.56

-0.62%↓

ABT

109.39

+0.52%↑

ISRG

476.98

-0.36%↓

JNJ

235.44

+0.84%↑

UNH

276.85

-1.86%↓

TMO

566.56

-0.62%↓

ABT

109.39

+0.52%↑

ISRG

476.98

-0.36%↓

JNJ

235.44

+0.84%↑

UNH

276.85

-1.86%↓

TMO

566.56

-0.62%↓

ABT

109.39

+0.52%↑

ISRG

476.98

-0.36%↓

Search

Charles River Laboratories International Inc

Ouvert

SecteurSoins de santé

199.16 -0.84

Résumé

Variation du prix de l'action

24h

Actuel

Min

197.8

Max

203.1

Chiffres clés

By Trading Economics

Revenu

2.9M

56M

Ventes

-27M

1B

BPA

2.43

Marge bénéficiaire

5.529

Employés

18,700

EBITDA

-23M

198M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+3.91% upside

Dividendes

By Dow Jones

Prochains Résultats

18 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.1B

11B

Ouverture précédente

200

Clôture précédente

199.16

Sentiment de l'Actualité

By Acuity

50%

50%

152 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Charles River Laboratories International Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

3 févr. 2026, 23:11 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Silicon Laboratories Shares Up On Report of $7 Billion Texas Instruments Acquisition Deal

3 févr. 2026, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 févr. 2026, 23:50 UTC

Market Talk

Nikkei May Decline After Hitting All-Time High -- Market Talk

3 févr. 2026, 23:42 UTC

Market Talk

Gold Edges Lower on Possible Technical Correction -- Market Talk

3 févr. 2026, 23:41 UTC

Acquisitions, Fusions, Rachats

KKR Makes AI Play With $10.9B Asia Data-Center Deal

3 févr. 2026, 23:38 UTC

Résultats

AMD Sales Climb on Help From Data-Center Business -- Update

3 févr. 2026, 23:29 UTC

Acquisitions, Fusions, Rachats

KKR-Consortium Deal in STT GDC Is One of the Largest Digital-Infrastructure Transactions in Southeast Asia

3 févr. 2026, 23:27 UTC

Acquisitions, Fusions, Rachats

Netflix, Warner Defend Proposed Deal in Senate Hearing -- WSJ

3 févr. 2026, 23:25 UTC

Acquisitions, Fusions, Rachats

KKR-Consortium Expects Deal to Close by Early 2H of 2026

3 févr. 2026, 23:23 UTC

Acquisitions, Fusions, Rachats

KKR Consortium With Singtel to Own 75% and 25% Stake in ST Telemedia Global Data Centres

3 févr. 2026, 23:22 UTC

Acquisitions, Fusions, Rachats

KKR-Led Consortium to Buy Singapore-Based Global Data-Center Provider Valued at S$13.8B

3 févr. 2026, 23:19 UTC

Market Talk

Australia Gold Miners Tipped to Rally Higher -- Market Talk

3 févr. 2026, 23:19 UTC

Market Talk

Global Equities Roundup: Market Talk

3 févr. 2026, 22:56 UTC

Principaux Mouvements du Marché
Acquisitions, Fusions, Rachats

Silicon Laboratories Shares Up On Report of $7B Texas Instruments Acquisition Deal

3 févr. 2026, 22:40 UTC

Résultats

Amdocs Extends Collaboration With T-Mobile

3 févr. 2026, 22:39 UTC

Résultats

Amdocs 1Q Adj EPS $1.81

3 févr. 2026, 22:39 UTC

Résultats

Amdocs 1Q Rev $1.16B

3 févr. 2026, 22:39 UTC

Résultats

Amdocs 1Q EPS $1.45 >

3 févr. 2026, 22:38 UTC

Résultats

Amdocs: Shimie Hortig to Succeed Shuky Sheffer as President and CEO, Effective March 31

3 févr. 2026, 22:30 UTC

Acquisitions, Fusions, Rachats

Bob Iger's Second Time as CEO Wasn't Great for the Stock. He Still Leaves Behind A Strong Legacy. -- Barrons.com

3 févr. 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

Texas Instruments Nearing $7B Deal for Silicon Laboratories, Sources Tell FT

3 févr. 2026, 22:14 UTC

Résultats

AMD Expects to Scale AI Business to Tens of Billions in Annual Sales in 2027, CEO Says

3 févr. 2026, 22:13 UTC

Résultats

AMD Expects Data-Center Unit Sales to Jump More Than 60% a Year Over Next Three to Five Years, CEO Says

3 févr. 2026, 22:12 UTC

Résultats

AMD in Talks With Several Companies About At-Scale, Multi-Year Chip Deployments, CEO Says

3 févr. 2026, 22:10 UTC

Résultats

AMD CEO: Eight of 10 Biggest AI Companies Use Instinct Chip to Power Production Workloads

3 févr. 2026, 22:10 UTC

Résultats

Blackstone Stock, Alternative Managers, BDCs Dive as Software Woes Infect Private Credit -- Barrons.com

3 févr. 2026, 22:10 UTC

Market Talk

Key Drivers Underpinning Shaw's Bullish View of Gold Intact -- Market Talk

3 févr. 2026, 22:10 UTC

Résultats

AMD CEO: Enterprises Are Modernizing Data Centers to Have Compute Needed for New AI Workflows

3 févr. 2026, 22:09 UTC

Résultats

AMD CEO: Hyperscalers Expanding Infrastructure to Meet Growing Cloud-Services Demand in AI

3 févr. 2026, 22:09 UTC

Résultats

AMD CEO: Demand Accelerated Across Data Center, Gaming and PC

Comparaison

Variation de prix

Charles River Laboratories International Inc prévision

Objectif de Prix

By TipRanks

3.91% hausse

Prévisions sur 12 Mois

Moyen 221.55 USD  3.91%

Haut 265 USD

Bas 170 USD

Basé sur 13 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

13 ratings

9

Achat

4

Maintien

0

Vente

Score Technique

By Trading Central

117.16 / 144.77Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Bearish Evidence

Sentiment

By Acuity

152 / 352Classement par Soins de santé

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat